Senses Disorder TRIZ Cases

Iontophoresis drives ionized lutein across the cornea and sclera to reach the posterior retina, avoiding invasive injections.

RNA interference reagents target mutant PABPN1 mRNA to suppress disease-causing protein expression in oculopharyngeal muscular dystrophy therapy.

Periodic administration of synthetic circular polyribonucleotides sustains protein expression by counteracting rapid degradation and immune recognition.

Implanted reservoirs deliver therapeutic agents directly to the eye via cannulas.

Copper-catalyzed triazole bridges preserve backbone conformation while enhancing thermal stability and aqueous solubility.

Core-1 positive microorganisms activate dendritic cells to stimulate T cell responses, preventing tumor growth and metastasis without severe side effects.

Boswellia low polar gum resin extract isolates specific sesquiterpenes and triterpenes to enhance in vivo bioavailability.

Formula I compounds inhibit lysophosphatidic acid receptor activity to treat fibrosis and cancer.

Isostearic acid in a foam carrier prevents chemical degradation of imiquimod, maintaining therapeutic efficacy.

3-O-β-D-glucopyranosyl-4-methylergost-7-en-3-ol inhibits lipid peroxide formation in biological systems.

Prostaglandin analog compounds reduce intraocular pressure while stimulating hair growth through targeted molecular design.

Anti-miR oligonucleotides neutralize pathogenic microRNAs to restore epithelial tissue permeability, preventing uncontrolled retinal pigment cell proliferation.

Antisense oligomers bind retained-intron pre-mRNA to promote constitutive splicing and increase functional protein levels.

Oxidized VEGF mini-trap molecules bind angiogenic targets with modified pharmacokinetics.

A new crystalline form of luminol produced using open-air evaporation yields phase-pure crystals with improved stability.

Novel bicyclic compounds inhibit autotaxin activity, reducing lysophosphatidic acid levels and treating renal, inflammatory, and cardiovascular diseases.

Inverting retroviral vector purification sequence concentrates particles before 0.22µm filtration, preventing yield loss during sterilization.

Essential sage oil and aloe destroy Demodex mites to treat blepharitis without steroid side effects.

Zwitterionic phospholipids stabilize room temperature formulations while reducing tear film evaporation and preventing vision dimming.

Heterocyclic compounds inhibit VEGFR and c-kit kinases to treat angiogenesis-related diseases.

Disulfide-bonded fibronectin fragments resolve hemorrhage risks from non-specific antagonists by selectively inhibiting alpha5beta1 and alphavbeta3 integrins.

Biaryl ether urea compounds inhibit fatty acid amide hydrolase to elevate brain anandamide levels for treating pain and depression.

Mutated tissue plasminogen activator proteins with altered lysine binding sites maintain fibrinolytic activity.

Specific amino acid substitutions in variant AAV2 capsid proteins overcome limited transduction efficiency of wild-type particles in retinal tissue.

ALK1 pathway antagonists inhibit angiogenesis and increase pericyte coverage in vascularized tissues.

Bispecific antibodies neutralize PDGFRbeta and VEGF-A, overcoming single-pathway resistance in cancer therapy.

Deuterated monoamine reuptake inhibitors extend half-life by substituting hydrogen with deuterium to reduce cytochrome P450 metabolism and lower toxicity.

Human recombinant antibodies with enhanced affinity target vascular endothelial growth factor A through variable region mutagenesis.

Segmented bifunctional histone deacetylase inhibitors combine zinc chelating warheads with recognition elements to resolve specificity and potency trade-offs.

Fc-region variants with specific amino acid mutations enable heterodimeric antibody assembly.

Extracting functional mitochondria bypasses complex cell replacement procedures to restore existing patient cell function and diagnose structural abnormalities.

Homozygous HLA-A, B, DR matching suppresses rejection responses in retinal pigment epithelial cell transplants.

A heterocyclic amide compound with a zinc-binding group inhibits matrix metalloproteinase-13 activity.

Modified polyribonucleotides evade immune recognition while delivering stable RNA templates for efficient protein translation.

Saturated benzyl malonate derivatives stabilize oxidation-sensitive cosmetic ingredients by eliminating double bonds susceptible to degradation.

Combining aryl analogs with conventional therapies restores NRF2 activity, reducing oxidative stress and inflammation while improving treatment reliability.

HPTP-beta inhibitors bind the target to regulate Tie-2 phosphorylation, addressing inadequate sustained vascular stabilization in diabetic retinopathy.

SCV-07 modulates immune response via Th1 shift, reducing eosinophilia and bronchial hyperreactivity.

Segmented PHD inhibitors with specific structural formulas stabilize HIF to reduce inflammation in ischemic reperfusion injury.

Modifying substituents on the thiabenzo azulene backbone reduces central nervous system penetration while maintaining strong H1 receptor antagonism.

Topical sex steroids and cannabinoids activate cranial nerves to treat neurodegenerative symptoms without systemic absorption.

Composite peptides block gamma-c-subunit interactions, resolving the contradiction between broad-spectrum inhibition and therapeutic specificity.

A bifunctional decoy receptor fusion antibody binds blood-brain barrier receptors to transport therapeutic proteins into the central nervous system.

Selective binding to misfolded transthyretin distinguishes pathological variants from native proteins, enabling accurate diagnosis of amyloid diseases.

Engineered ankyrin repeat proteins bind VEGF-Axxx to block angiogenesis while sparing anti-angiogenic isoforms.

High dose aflibercept combined with specific excipients slows ocular clearance to reduce injection frequency for nAMD treatment.

Hydroxypropyl-γ-cyclodextrin removes lysosomal cholesterol accumulation, avoiding renal and pulmonary disorders associated with HPBCD.